Results 181 to 190 of about 16,087 (221)

Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis.

Cardiorenal Med
Huang W, Guan T, Yan Z, Cui Y, Bi S, Wu M, Yuan D.   +6 more
europepmc   +1 more source

Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study. [PDF]

Front Endocrinol (Lausanne)
Wang Y, Li H, Zhang Z, Kong X, Li H, Qian W, Ma J.   +6 more
europepmc   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Selective sugar transport supports Proteus mirabilis fitness in the urinary tract. [PDF]

PLoS Pathog
Shea AE, Kuo S, Gupta S, Smith SN, Appaji T, Mitchell T, Mobley HLT, Pearson MM.   +7 more
europepmc   +1 more source

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension. [PDF]

Front Endocrinol (Lausanne)
Li W, Li R, Li S, Li Z, Ma J, Wu F, Chen C.   +6 more
europepmc   +1 more source

Natriuretic Effect of Dapagliflozin in Cirrhosis With Ascites: A Randomized, Placebo-Controlled Crossover Trial. [PDF]

Int J Hepatol
Kongphakdee N, Piewchan S, Sanpawithayakul K, Chonprasertsuk S, Siramolpiwat S.   +4 more
europepmc   +1 more source

Issue Information

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1243-1246, August 2026.
wiley   +1 more source

Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal.

JAMA Health Forum
El-Kilani ZS, Kulkarni S, Levy JF.
europepmc   +1 more source